Related Experiment Video
Updated: Apr 22, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Integrated cell-based platform to study EGFR activation and transactivation
Marie-Elaine Caruso1, Paule Clément, Stéphane Parent
1PerkinElmer BioSignal, Inc., Montreal, Canada .
Abstract:
The epidermal growth factor receptor (EGFR) pathway is one of the most deregulated molecular pathways in human epithelial cancers. Many approved drugs were optimized to directly target EGFR but yielded only modest clinical improvement in cancer patients due to low efficacy and drug resistance. Transactivation of EGFR by other cell surface receptors such as G-protein-coupled receptors (GPCRs) was proposed to explain this lack of efficacy. Even if direct EGFR activation and transactivation by GPCR contribute to the activation of the same signaling pathways, they are often studied as independent events resulting in partial investigation of a drug's mechanism of action. We present a novel high-throughput approach that integrates interrogation of direct activation of EGFR and its transactivation via GPCR activation. Using distinct technology platforms, three readouts were used to measure (1) direct activation of GPCR via cyclic adenosine monophosphate (cAMP) detection, (2) direct activation of EGFR through the release of intracellular Ca(2+), and (3) EGFR transactivation by GPCR using the detection of p-extracellular-signal-regulated kinases 1/2 (p-ERK1/2). In addition to being simple, quick, and homogenous, our methods were shown to be more sensitive than those in current use. These enabling tools should improve the knowledge pertaining to GPCRs and receptor tyrosine kinases trans-regulation and facilitate the design of more potent and better targeted new therapeutic strategies.
Insights
This study introduces a new high-throughput method to simultaneously measure epidermal growth factor receptor (EGFR) activation and its transactivation by G-protein-coupled receptors (GPCRs). This approach enhances understanding of cancer drug resistance and aids in developing targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The epidermal growth factor receptor (EGFR) pathway is frequently deregulated in epithelial cancers.
- Current EGFR-targeted drugs show limited efficacy due to resistance, partly explained by receptor transactivation.
- EGFR activation and GPCR-mediated transactivation are often studied separately, leading to incomplete understanding.
Purpose of the Study:
- To develop a novel high-throughput approach for simultaneously assessing direct EGFR activation and GPCR-mediated EGFR transactivation.
- To provide a more comprehensive understanding of the molecular mechanisms underlying EGFR pathway dysregulation in cancer.
- To facilitate the design of improved cancer therapeutics targeting EGFR and GPCR signaling.
Main Methods:
- Integration of distinct technology platforms for multiplexed measurements.
- Detection of G-protein-coupled receptor (GPCR) activation via cyclic adenosine monophosphate (cAMP).
- Measurement of epidermal growth factor receptor (EGFR) activation using intracellular Ca(2+) release.
- Quantification of EGFR transactivation by GPCRs through p-extracellular-signal-regulated kinases 1/2 (p-ERK1/2) detection.
Main Results:
- The developed method is simple, rapid, and homogenous.
- The assay demonstrated higher sensitivity compared to existing methods.
- Successfully integrated measurements of direct EGFR activation and GPCR-mediated transactivation.
Conclusions:
- The novel high-throughput approach provides a more complete picture of EGFR pathway regulation.
- This method enhances knowledge of GPCR and receptor tyrosine kinase trans-regulation.
- Enables the development of more potent and precisely targeted cancer therapies.
